US FDA concludes remote record review of Unit 3 of Shilpa Medicare Ltd

US FDA has concluded Remote Record Review of Shilpa Medicare Limited ('SML' or 'the Company), Unit III, Research and Development facility situated at Dabaspet, Bengaluru, Karnataka without any objectionable conditions or observations. The review was conducted during 15th to 18th Nov 2021.

Shilpa Medicare Limited, Unit III, R&D facility is involved in development of formulations (generics, complex generics and innovative products) and providing advanced analytical services.

Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 560.75 as compared to the previous close of Rs. 564.70. The total number of shares traded during the day was 8236 in over 645 trades.

The stock hit an intraday high of Rs. 572.20 and intraday low of 558.90. The net turnover during the day was Rs. 4645400.00.

Source : Equity Bulls

Keywords

ShilpaMedicareLimited INE790G01031 SHILPAMED Pharmaceuticals USFDA RemoteRecordReview